INCY Incyte

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Biopharmaceutical company focused on development, commercialization, and licensing of innovative drugs
• • New products emphasized: NIKTIMVO commercial launch in Q1 2025; ZYNYZ approved for squamous cell anal carcinoma in Q2 2025

Risk Factors

• • Regulatory risk: ongoing contract dispute settlement expense of $242M recognized in fiscal 2025
• • Macroeconomic exposure: 93% of total revenues ($4.8B of $5.1B) from U.S. market concentration

Management Discussion & Analysis

• • Revenue $3.5B, up 8% YoY driven by JAKAFI and new product growth
• • Operating margin 22.4% vs 19.7% reflecting improved cost efficiencies

Management Discussion & Analysis

• • Revenue $1.37B Q3 2025, up 20% YoY from $1.14B in Q3 2024, driven by JAKAFI $791.1M (+$49.9M) and OPZELURA $188M (+$48.7M) growth
• • Net income $424.2M Q3 2025 vs $106.5M Q3 2024; Operating margin not explicitly stated but net income increased ~298% YoY

Risk Factors

• • New risk: Increased patient access challenges from PBM rebate negotiations, especially for OPZELURA, triggered by ongoing formulary coverage agreements
• • Material update: FDA added boxed warnings for JAKAFI and OPZELURA in Sept 2021 citing risks of cardiovascular events, thrombosis, mortality negatively impacting sales prospects

What are the latest INCY SEC filings in 2026?

Incyte (INCY) has filed a 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 28, 2025, an 8-K current report on April 28, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did INCY file its most recent 10-K annual report?

Incyte (INCY) filed its most recent 10-K annual report on February 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view INCY 10-Q quarterly reports?

Incyte (INCY)'s most recent 10-Q quarterly report was filed on October 28, 2025. SignalX displays every INCY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has INCY filed recently?

Incyte (INCY)'s most recent 8-K was filed on April 28, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find INCY insider trading activity (Form 4)?

SignalX aggregates every INCY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does INCY file with the SEC?

Incyte (INCY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new INCY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Incyte (INCY).

What is INCY's SEC CIK number?

Incyte (INCY)'s SEC CIK (Central Index Key) number is 879169. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 879169 to look up all INCY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find INCY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Incyte (INCY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.